Metabolic dysfunction associated steatotic liver disease, or MASLD, is one of the fastest growing chronic liver conditions worldwide, yet advanced fibrosis frequently remains undiagnosed until later stages. A recent multicenter study published in Hepatology Communications evaluates practical, two step care pathways to improve early identification of patients at risk for advanced MASLD fibrosis across primary and hospital care. The study brings together an international network of clinical experts, including Manuel Castro Cabezas, Scientific Officer at P95 Julius Clinical, reflecting the organization’s continued involvement at the forefront of cardiometabolic and liver disease research.

Read the full study →

The findings show that structured, two step diagnostic approaches can significantly improve detection of advanced fibrosis while reducing unnecessary specialist referrals. By combining widely accessible first line risk scores with confirmatory testing such as vibration controlled transient elastography, these pathways offer a scalable and efficient model for implementation in real world care. The participation of an expert affiliated with Julius Clinical underscores a broader commitment to advancing evidence-based strategies that bridge clinical research and everyday practice, supporting earlier diagnosis and better outcomes for patients with MASLD.